Summarize the article with AI
Retatrutide Side Effects: The Short Answer
The most common side effects reported in retatrutide's Phase 3 trials were gastrointestinal: nausea, diarrhea, constipation and vomiting. In announcing TRIUMPH-1, TRIUMPH-4 and TRANSCEND-T2D-1, Lilly said the types of adverse events were generally consistent with trials of other incretin-based therapies, the class that includes semaglutide and tirzepatide. In TRIUMPH-1, the pivotal obesity trial, published in full in September 2026, 11.2% of participants on the highest dose stopped treatment because of adverse events, against 4.6% on placebo. The published paper also shows that low blood pressure was more common on retatrutide. In TRANSCEND-T2D-2, the first Phase 3 trial to compare retatrutide directly with another incretin medicine, gastrointestinal side effects were broadly similar to those on semaglutide 2 mg, while dysesthesia and stopping treatment because of side effects were more common on retatrutide.
One side effect has drawn more attention than the rest: dysesthesia, an altered sense of touch often described as skin sensitivity. It was reported far more often than with tirzepatide, but it is not unique to retatrutide — semaglutide's US label lists it too, at 22% on its highest dose. In TRANSCEND-T2D-2 it was reported by 6.5% of participants on retatrutide 12 mg against 2.7% on semaglutide 2 mg.
Trials count every adverse event that occurs during treatment, whether or not the drug caused it, which is why placebo groups report them too. The TRIUMPH-1 figures below come from the paper published in the New England Journal of Medicine; the others come from Lilly's announcements, although TRIUMPH-2 and TRANSCEND-T2D-1, a trial in type 2 diabetes, have also been published in full in The Lancet. TRANSCEND-T2D-2 has been reported only in a company announcement so far.
Retatrutide Side Effects by Dose
TRIUMPH-1 enrolled 2,339 adults with obesity or overweight and without diabetes, and compared three doses with placebo over 80 weeks.
Nausea, vomiting, dizziness and the share who stopped because of adverse events rose steadily with the dose. Not everything did: diarrhea and fatigue were slightly less common on 12 mg than on 9 mg, abdominal pain was least common on 9 mg, and upper respiratory tract infections, which occurred at close to the placebo rate, were most frequent on 4 mg. At 12 mg, nausea, diarrhea, constipation and vomiting were roughly 2.4 to 5.3 times as common as on placebo, and dysesthesia more than ten times. All figures come from the published paper except the per-dose urinary tract infection rates, which come from Lilly's announcement; the paper gives only a range, 7.5% to 8.7% across the three doses against 5.3% on placebo, and says 92% of these infections occurred in women and none led to stopping treatment. Apart from urinary tract infections, we found no side effects reported separately for women and men in the paper or its supplementary appendix; what the trial showed for each sex is covered in retatrutide in women vs men.
Side Effects Across the Placebo-Controlled Phase 3 Trials
Results have been announced from six Phase 3 trials. Five compared retatrutide with placebo, and the table shows the main adverse events reported for the 12 mg dose in each, with the placebo rate in parentheses; "Not listed" means the source for that trial gave no figure for that event. The TRIUMPH-1 column comes from the published paper, except urinary tract infections, and the other columns from Lilly's announcements. TRIUMPH-3's announcement also listed hyperglycemia, which was more common on placebo (13.4%) than on 12 mg (3.1%). The sixth trial, TRANSCEND-T2D-2, compared retatrutide with semaglutide instead of placebo and is covered separately below.
Nausea rose with the dose in all five trials, though only slightly in TRIUMPH-3 (21.7% on 9 mg, 22.4% on 12 mg). Diarrhea did not follow the dose as closely: it was lower on 12 mg than on 9 mg in four of the five. Rates also differed from trial to trial — nausea at 12 mg ranged from 22.4% in TRIUMPH-3 to 43.2% in TRIUMPH-4. The trials enrolled different populations and ran for different lengths of time, so the columns are not directly comparable.
How Many People Stopped Because of Side Effects
The share who stopped generally rose with the dose, with one exception: in TRIUMPH-2, more people stopped on 9 mg than on 12 mg. In TRANSCEND-T2D-2, which had no placebo group, the rates on retatrutide were higher than the 2.7% on semaglutide 2 mg. Population matters too. In TRIUMPH-4, a trial in people with knee osteoarthritis, the company said the rates were highly correlated with baseline BMI and included people who stopped because of perceived excessive weight loss; among participants with a BMI of 35 or more, the 12 mg figure was 12.1% rather than 18.2%. Trial length also differs: TRANSCEND-T2D-1 ran for 40 weeks, the others for 68 to 80.
The TRIUMPH-1 row shows the published paper's figures; the May 2026 announcement had given 4.1%, 6.9% and 11.3%, against 4.9% on placebo. The paper also reports that 0.3%, 1.0% and 5.3% of participants on 4 mg, 9 mg and 12 mg, and none on placebo, stopped because they or the site investigator considered their weight loss excessive or sufficient.
When Retatrutide Side Effects Start and How Long They Last
The TRIUMPH-1 paper describes the gastrointestinal events as mostly transient and mild or moderate, occurring most commonly during dose escalation, but neither the paper nor Lilly's announcements say how long individual episodes lasted. For TRANSCEND-T2D-1, the company said the most common adverse events — nausea, diarrhea and vomiting — occurred primarily during dose escalation, and in coverage of the trial's presentation at the American Diabetes Association meeting in June 2026 they were described as generally mild to moderate and easing over time.
The TRIUMPH-1 paper's supplementary appendix adds charts of how many participants had each gastrointestinal side effect at any one time, among those still being followed (Figure S21). Read from those charts, and therefore approximate: on 12 mg, the share with nausea peaked at about 20% between roughly weeks 16 and 24, then fell to under 10% after about week 48 and to around 5% by week 80; on 9 mg it peaked at about 17%. Diarrhea on 12 mg peaked at about 10% around week 16 and fell to about 2% in the final months, and vomiting never affected more than about 6% at once. Constipation was the most persistent: on 12 mg, roughly 5% to 10% of participants had it at any one time from the first weeks to the end. On placebo, vomiting stayed below 1% and the other three at about 1% to 4% at any one time. For nausea, diarrhea and constipation, most participants affected at any one time had mild symptoms; vomiting was about evenly split between mild and moderate on 4 mg and 9 mg. Severe cases were few on every dose. The charts show how common each event was over time, not how long a single episode lasted.
The 48-week Phase 2 trial, published in full in 2023, gives the same picture in more detail: gastrointestinal adverse events occurred primarily during dose escalation, were mostly mild to moderate and were more frequent at higher doses, and the authors described them as transient.
For TRIUMPH-1, TRIUMPH-2, TRIUMPH-3, TRANSCEND-T2D-1 and TRANSCEND-T2D-2, the company reported that dysesthesia and urinary tract infections were generally mild to moderate and that the majority resolved during treatment. For TRIUMPH-4, it said the dysesthesia events were generally mild and rarely led to discontinuation. What happened to these events after people stopped treatment is not reported separately in the announcements or in the TRIUMPH-1 paper.
Dysesthesia: What Is Known So Far
Dysesthesia is an altered sense of touch: tingling, burning, or ordinary contact feeling unpleasant or painful. It was reported more often on retatrutide than on placebo in all five placebo-controlled Phase 3 trials with results so far, and more often than on semaglutide 2 mg in TRANSCEND-T2D-2: 4.8% and 6.5% on 9 mg and 12 mg, against 2.7%. At 12 mg the rate ranged from 4.4% in TRANSCEND-T2D-1 to 20.9% in TRIUMPH-4; in TRIUMPH-1 it was 12.5%, against 0.9% on placebo. It rose with the dose in TRIUMPH-2 and TRIUMPH-4, and in TRIUMPH-1 from 4 mg to 9 mg, but not in TRIUMPH-3, where both doses had 6.4%, or in TRANSCEND-T2D-1. The published TRIUMPH-1 paper labels the category "dysesthesia: skin burning sensation and related adverse events" and describes it, together with injection-site reactions and low blood pressure, as mostly mild or moderate and nonserious; it does not say how long it lasted or what caused it.
Related events had appeared before. The Phase 2 trial reported cutaneous hyperesthesia and skin sensitivity in 7% of participants on retatrutide overall — 13% on the 12 mg dose — and 1% on placebo; none were severe, and none led to discontinuation.
Dysesthesia is not unique to retatrutide. Semaglutide's US label, revised in June 2026, lists it for both the 2.4 mg and 7.2 mg injections: 2% of patients against 1% on placebo in the three trials pooled for the 2.4 mg dose, and 22% on 7.2 mg and 6% on 2.4 mg, against 0.3% on placebo, in the later trials that tested the higher dose. The label says the incidence increases with dose. Tirzepatide's US label reports dysesthesia in 0.4% of patients on 15 mg, against 0.1% on placebo.
On these figures, retatrutide 12 mg in TRIUMPH-1 had a higher rate than semaglutide 2.4 mg on either measure and a far higher rate than tirzepatide, but a lower rate than semaglutide 7.2 mg. These are comparisons across different trials, and the sources may not count the same things: semaglutide's figures include related sensations such as paresthesia, burning and sensitive skin, while the TRIUMPH-1 paper describes its category only as skin burning sensation and related events, and neither the tirzepatide label nor Lilly's other announcements say which terms their figures include. In TRANSCEND-T2D-2, where the two drugs were compared directly, dysesthesia was also more common on retatrutide, although the participants had type 2 diabetes and the semaglutide dose was 2 mg rather than the 2.4 mg used for weight loss.
Does Retatrutide Cause Fatigue?
Fatigue was reported more often on retatrutide than on placebo. In TRIUMPH-1 it affected 7.4%, 10.6% and 10.1% of participants on 4 mg, 9 mg and 12 mg, against 3.6% on placebo. In the 48-week Phase 2 trial, it was reported by 10% of participants on 12 mg and 4% on placebo. The TRIUMPH-1 paper does not say how long it lasted.
Approved drugs in the same class list fatigue too. Tirzepatide's US label reports it in 5%, 6% and 7% of patients on 5 mg, 10 mg and 15 mg, against 3% on placebo, in two pooled weight-reduction trials. Semaglutide's label reports 11% on 2.4 mg against 5% on placebo in three pooled trials, and 11% on 7.2 mg in the later trials of the higher dose. Both labels count related terms under fatigue — asthenia for both, and lethargy and malaise for tirzepatide — so the figures may not count the same things. On these numbers, fatigue on retatrutide 9 mg and 12 mg was close to the rate for semaglutide 2.4 mg and above that for tirzepatide; these are comparisons across separate trials, not head-to-head results.
Injection-Site Reactions in the Retatrutide Trials
Injection-site reactions rose with the dose in TRIUMPH-1: 5.5%, 8.9% and 12.2% of participants on 4 mg, 9 mg and 12 mg, against 3.8% on placebo. The paper describes them, together with dysesthesia and low blood pressure, as mostly mild or moderate and nonserious. In the Phase 2 trial, 5 of 62 participants on 12 mg (8%) had an injection-site reaction, against none of the 70 on placebo.
The approved drugs' labels report a wide range. Tirzepatide's lists injection-site reactions in 6%, 8% and 8% of patients on 5 mg, 10 mg and 15 mg, against 2% on placebo, and says they were more frequent in patients who developed antibodies to the drug (11.3%) than in those who did not (1%). Semaglutide's lists them in 1.4% of patients against 1% on placebo. The labels group different terms under this heading, such as bruising, redness, itching, pain or swelling at the site, so the rates are not directly comparable.
Does Retatrutide Cause Hair Loss?
Hair loss has not been reported as a common side effect in the retatrutide trials so far. In the Phase 2 trial, it does not appear in the paper's table of adverse events reported by at least 5% of all participants, or in the supplementary table of events reported by at least 5% of any dose group. It is also not among the adverse events in the TRIUMPH-1 paper, which lists events reported by at least 10% of participants in any group and events of special interest, and we found no mention of it in the paper's supplementary appendix, which does not include a full list of adverse events.
That does not show that retatrutide does not cause hair loss. Approved drugs in the class list it on their US labels, and both labels say it was associated with weight reduction. Tirzepatide's label reports hair loss in 5%, 4% and 5% of patients on 5 mg, 10 mg and 15 mg, against 1% on placebo; it was far more common in women (7.1%) than in men (0.5%), and no patients on tirzepatide stopped treatment because of it. Semaglutide's label reports 3.3% on 2.4 mg against 1% on placebo (4% of women and 0.9% of men), and 5.8% on 7.2 mg (8.4% of women, 0.2% of men) in the trials of the higher dose. Whether the same pattern holds for retatrutide cannot be told from the published data.
The tirzepatide and semaglutide figures come from pooled trials described on their US labels; the retatrutide figures come from a single trial. The trials differed in length, population and how events were grouped, so these are comparisons across separate trials, not head-to-head results.
How Retatrutide Side Effects Compare With Semaglutide and Tirzepatide
The gastrointestinal and discontinuation figures come from each drug's pivotal obesity trial; the dysesthesia figures for tirzepatide and semaglutide come from their US labels, as described above — for tirzepatide, pooled from SURMOUNT-1 and SURMOUNT-2. The trials differed in length and population, so these are comparisons across separate trials, not head-to-head results. Weight loss on the same basis is compared in retatrutide vs tirzepatide vs semaglutide.
On those terms, tirzepatide had the lowest rate of every gastrointestinal event, though its placebo group also had the lowest rates. Retatrutide 12 mg and semaglutide 2.4 mg were within three percentage points of each other on all four. More people stopped retatrutide because of adverse events — 11.2%, against 7.0% for semaglutide and 6.2% for tirzepatide, with placebo rates of 4.6%, 3.1% and 2.6%.
The First Phase 3 Head-to-Head Trial: TRANSCEND-T2D-2
TRANSCEND-T2D-2 compared retatrutide 9 mg and 12 mg directly with semaglutide 2 mg, the highest approved dose of injectable semaglutide for type 2 diabetes, in 1,298 adults whose type 2 diabetes was inadequately controlled on metformin, with or without an SGLT2 inhibitor. It ran for 80 weeks and was open-label, so participants knew which drug they were taking, which can affect how side effects are reported. The figures come from the company's topline announcement of October 28, 2026; the full results have not yet been published.
Nausea was reported at almost the same rate on 9 mg as on semaglutide (21.2% against 21.3%) and slightly more often on 12 mg (23.8%), and diarrhea somewhat more often on 12 mg. Constipation and dyspepsia were less common on both retatrutide doses, and vomiting was less common on 9 mg and more common on 12 mg. Dysesthesia and stopping because of side effects were more common on retatrutide; on 12 mg, the share who stopped was nearly three times that on semaglutide. The announcement did not report serious adverse events, low blood sugar or heart rate. Because the participants had type 2 diabetes and the semaglutide dose was lower than the 2.4 mg used for weight loss, the results do not show how the two drugs compare in people with obesity alone. The weight and A1C results are in retatrutide vs semaglutide head to head.
Low Blood Pressure, Heart Effects and Rarer Side Effects
The company's announcements concentrate on the most common adverse events. The published TRIUMPH-1 paper also reports less common ones, including some, such as gallbladder problems and pancreatitis, that carry warnings on the labels of approved drugs in this class:
Low blood pressure stands out. It became more common as the dose rose, and the investigators wrote that it was more common in participants who were also taking blood pressure medicines; they described it, together with dysesthesia and injection-site reactions, the most frequent adverse events of special interest that were more common on retatrutide, as mostly mild or moderate and nonserious. Dizziness was reported in 12.0% of participants on 12 mg against 3.1% on placebo. Pulse rate rose on retatrutide, peaking at 20 weeks on 9 mg and 12 mg and decreasing after that; at week 80 it was on average 1.5 to 2.7 beats per minute higher than at the start, against 0.3 lower on placebo, according to the supplementary appendix. The data are covered in why retatrutide increases heart rate.
For pancreatitis, the investigators wrote that the small numbers do not permit conclusions about a treatment effect. The appendix also shows that pancreatic enzymes rose on average: at week 80, lipase was about 28% to 31% higher than at the start on retatrutide, against 6% on placebo, and pancreatic amylase about 20% to 22% higher, against 5%, with average values remaining within the normal range. For the thyroid, the paper notes that neither case on retatrutide was medullary thyroid cancer and that there was no C-cell hyperplasia, and the appendix shows that average calcitonin, a marker of C-cells, rose by 12% to 15% on retatrutide and fell by 2% on placebo while staying within the normal range. The three severe or serious liver disorders, all on 12 mg, were a case of acute cholestatic hepatitis A, acute ischemic hepatitis most likely due to dehydration associated with Clostridium difficile colitis, and raised liver enzymes associated with worsening gallstone disease. Four participants on retatrutide and two on placebo died. One death, on 12 mg, was adjudicated as cardiovascular; it occurred in a participant with known heart failure 189 days after stopping retatrutide. The others were a motor vehicle accident and two sudden deaths, one noncardiovascular and one of undetermined cause, on 9 mg, and a motor vehicle accident and a gunshot wound on placebo. The investigators noted that the trial was not powered to assess cardiovascular safety. A trial of this size also cannot show how often rare events occur.
Cardiovascular events were counted more closely in TRIUMPH-3, which enrolled 1,949 people with a BMI of 35 or more and established cardiovascular disease. There were 27 major cardiovascular events — cardiovascular death, heart attack or stroke — among participants randomized to retatrutide (9 mg and 12 mg combined) and 23 among those randomized to placebo, a hazard ratio of 1.12 (95% confidence interval 0.64 to 1.96). On a broader measure that also counts death from any cause, heart failure events and coronary revascularization, there were 44 and 52, a hazard ratio of 0.82 (0.55 to 1.22). The company said such events occurred less often than anticipated in both groups. Twice as many participants were assigned to placebo as to each dose, so the combined retatrutide group and the placebo group were about the same size.
These pre-specified figures count all events during the study, whether or not participants were still taking their treatment. A further analysis that the company notes was not pre-specified, leaving out events more than 35 days after treatment stopped, gave hazard ratios of 0.92 (0.51 to 1.65) for the narrower measure and 0.73 (0.47 to 1.12) for the broader one. With this few events, every one of these confidence intervals includes no difference, so the results cannot show whether retatrutide raises or lowers cardiovascular risk. A separate trial with an enrollment goal of 10,000 people, TRIUMPH-Outcomes, is designed to determine whether retatrutide lowers serious heart-related complications or prevents worsening kidney function; the trial listing runs to February 2029.
The 48-week Phase 2 trial, with 338 adults, adds some detail. Heart rate rose with the dose, peaking at 24 weeks and declining after that. Cardiac arrhythmias — a category covering supraventricular arrhythmias and conduction disorders — were reported in 11% of participants on 12 mg and 3% on placebo; all were mild to moderate except one severe case of QT prolongation in a participant treated with ondansetron. Serious adverse events occurred in 4% of both the retatrutide and placebo groups. One participant on 12 mg had acute pancreatitis, and three on retatrutide had gallbladder events. A trial of this size cannot show how often rarer events occur.
In TRANSCEND-T2D-1, according to coverage of its presentation, no severe hypoglycemia was reported, and the two deaths during the study, both in the 4 mg group, were deemed unrelated to the study drug.
Why This Page Has No Management Advice
Many articles about retatrutide side effects include week-by-week dosing schedules, injection tips and advice on which medicines to take for nausea. This one does not, deliberately. Retatrutide has no approved dose or label, so there is no approved way to use it, and in the trials side effects were handled by the investigators running them.
Retatrutide is available only through clinical trials and a limited expanded-access program, and Lilly says no one can legally sell it for human use. The company warns that products sold online under the name "may contain unknown ingredients, harmful contaminants and impurities" — so the side effects reported in the trials say nothing reliable about what those products might do.
Retatrutide Side Effects in Summary
In Phase 3, the most common side effects of retatrutide were gastrointestinal, and nausea became more common at higher doses. At 12 mg in TRIUMPH-1, gastrointestinal rates were close to those of semaglutide 2.4 mg in its pivotal trial and above those of tirzepatide 15 mg, and more people stopped treatment because of adverse events than in either approved drug's pivotal trial — comparisons across separate trials, not head-to-head results. Dysesthesia was reported far more often than with tirzepatide, but semaglutide's label lists it too, at 2% to 6% on 2.4 mg and 22% on 7.2 mg. In TRANSCEND-T2D-2, the first Phase 3 head-to-head trial, gastrointestinal rates were broadly similar to those on semaglutide 2 mg in people with type 2 diabetes, but dysesthesia was more common and more people stopped retatrutide because of side effects.
The published TRIUMPH-1 paper adds detail the announcements did not, most notably low blood pressure, reported in 8.8% of participants on 12 mg against 0.9% on placebo. Charts in its appendix show nausea, vomiting and diarrhea becoming less common after the first months, while constipation persisted at a lower level. How long individual episodes last and how often rare events occur are still open questions (see retatrutide long-term safety) that longer follow-up and, if retatrutide is approved, an FDA label would address.
Sources
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. N Engl J Med. Published September 29, 2026; updated October 22, 2026. DOI: 10.1056/NEJMoa2604169. (TRIUMPH-1)
- Jastreboff AM, Kaplan LM, Davies MJ, et al. Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity. Supplementary Appendix, Figure S21 and Table S12. N Engl J Med. 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial. May 21, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, delivered weight loss of up to an average of 71.2 lbs along with substantial relief from osteoarthritis pain in first successful Phase 3 trial. December 11, 2025.
- Eli Lilly. Lilly's triple agonist, retatrutide, successful in two additional Phase 3 obesity trials, delivering significant improvements in weight and A1C. July 23, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, delivered substantial weight loss and A1C reduction, underscoring its potential promise for people with obesity and type 2 diabetes. September 29, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, demonstrated significant reductions in A1C and weight in first Phase 3 trial for treatment of type 2 diabetes. March 19, 2026.
- Eli Lilly and Company. Lilly's retatrutide delivered greater A1C reduction and more than double the weight loss of Ozempic's highest approved dose in head-to-head trial. Press release, October 28, 2026. (TRANSCEND-T2D-2)
- Lilly Medical. How did retatrutide compare with semaglutide 2 mg in adults with type 2 diabetes in TRANSCEND-T2D-2? Reviewed October 28, 2026.
- Eli Lilly. Lilly's triple agonist, retatrutide, drove substantial improvements in weight, A1C, knee osteoarthritis pain, and obstructive sleep apnea, demonstrating its remarkable potential to treat obesity and its complications. June 6, 2026.
- Cleveland Clinic Journal of Medicine. Retatrutide yields substantial improvements in type 2 diabetes and obesity, phase 3 data from TRANSCEND-T2D-1 and TRIUMPH-1 show. ADA 2026 coverage, June 2026.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. N Engl J Med. 2023;389(6):514–526.
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial. Supplementary Appendix, Table S10. N Engl J Med. 2023;389(6):514–526.
- Eli Lilly. Lilly's SURMOUNT-1 results published in The New England Journal of Medicine show tirzepatide achieved between 16.0% and 22.5% weight loss in adults with obesity or overweight. June 4, 2022.
- Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. N Engl J Med. 2021;384(11):989–1002.
- Novo Nordisk. Wegovy (semaglutide) US prescribing information, section 6.1. Revised June 2026.
- Eli Lilly. US prescribing information for tirzepatide for weight reduction, section 6.1. Revised August 2026.
- Lilly Trials. The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults (TRIUMPH-Outcomes). NCT06383390, trial listing.
- Eli Lilly. What to know about retatrutide.
- STAT. Eli Lilly to allow more patients to apply for special access to unapproved obesity drug. August 3, 2026.
Medical Disclaimer: This article is for informational purposes only and is not medical advice. Retatrutide is investigational and is not approved by the FDA for any use. It is not available by prescription, and Lilly says no one can legally sell it for human use. The side effects described here are those reported in clinical trials under medical supervision.
Frequently asked questions
The most common side effects in the retatrutide trials were gastrointestinal. In TRIUMPH-1, on the highest dose of 12 mg, 42.4% of participants reported nausea, 32.0% diarrhea, 26.1% constipation and 25.3% vomiting, against 14.8%, 13.5%, 10.9% and 4.8% on placebo. Dysesthesia, an altered sense of touch, was reported by 12.5%, and low blood pressure by 8.8%.
Neither the TRIUMPH-1 paper nor Lilly's announcements report how long individual side effects lasted. Charts in the TRIUMPH-1 appendix show that the share of participants with nausea, vomiting or diarrhea at any one time peaked within roughly the first six months, around the end of the 16-week dose escalation, and then fell, while constipation persisted at a lower level. For five of the six reported Phase 3 trials, the company said most dysesthesia and urinary tract infection events resolved during treatment.
Diarrhea was one of the most common side effects in the trials. In TRIUMPH-1 it was reported by 25.2%, 34.1% and 32.0% of participants on 4 mg, 9 mg and 12 mg, against 13.5% on placebo. The paper does not say how long episodes lasted, but charts in its appendix show that the share with diarrhea at any one time on 12 mg peaked at about 10% around week 16 and fell to about 2% in the final months.
Hair loss has not been reported as a common side effect in the retatrutide trials. It does not appear among the adverse events reported in at least 5% of participants in the Phase 2 paper or its appendix, and we found no mention of it in the TRIUMPH-1 paper or its appendix. The US labels of tirzepatide and semaglutide list hair loss at 3% to 6% of patients, depending on the drug and dose, against 1% on placebo, and say it was associated with weight reduction and more common in women.



